Photobiomodulation Therapy Treatment on Facial Paralysis
Facial Paralysis
About this trial
This is an interventional treatment trial for Facial Paralysis focused on measuring Facial paralysis, photobiomodulation, ENoG, EMG, HB grading
Eligibility Criteria
Inclusion Criteria:
- (1) adults over 18 years of age and under 65 years of age. (2) had not received medicine, such as prednisolone. (3) had history of Bell's palsy, Ramsay Hunt syndrome, traumatic facial paralysis and history of otological surgery.
(4) Disease duration longer than two months.
Exclusion Criteria:
- (1) Complete facial paralysis (HB 6). (2) Greater than 90% denervation on ENoG. (3) No voluntary EMG activity. (4) No latency of early (R1) and late (R2, R2') components in blink reflex. (5) Serious mental illness or social problems, and neurological disorders. (6) Systemic disease, such as severe diabetes, malignant tumors and other serious consumptive diseases.
(7) Planning for pregnancy, in pregnancy or lactation.
Sites / Locations
- Beijing TongRen Hospital, Capital Medical University
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Photobiomodulation Group
Control Group
Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.